YAFO Acts as Exclusive Financial Advisor for AUM Biosciences in its collaboration & Licensing-out Transaction with Newsoara Biopharma

雅法担任AUM Biosciences独家顾问,完成与恒翼生物合作开发及商业许可交易

Click here to view the last 3 transactions. 点此查看雅法近期交易:

- Rhizen Pharmaceuticals: Ph2 Oncology Asset Licensing-out

临床二期抗肿瘤口服PI3K双重抑制剂中国授权

- Flexion: Approved Osteoarthritis-related Knee Pain Therapy Licensing-out

美国已上市治疗膝骨关节炎的长效药物中国授权

- Tarveda: Ph1 Oncology Asset Licensing-out including a Strategic Investment

临床一期抗肿瘤小分子药物偶联物中国授权

• AUM Biosciences and Newsoara Biopharma announce a 5-year transformational Strategic Partnership to co-develop and co-discover Next-Generation Cancer Therapeutics

• AUM Biosciences和Newsoara Biopharma(恒翼生物)宣布了一项为期5年的新型战略合作伙伴关系,双方将共同开发和共同发现下一代癌症治疗药物

• AUM grants Newsoara exclusive license in oncology for current and future pipeline for up to 6 oncology molecules in the Greater China Region
AUM授予恒翼生物至多6种肿瘤分子(现有资产及未来开发资产)在大中华地区的独家许可

• AUM will receive up to $135M in Near-term Development, Regulatory, and Commercial milestones for its current pipeline. Additionally, AUM will be eligible to receive Double Digit Royalty Payments
AUM将在近期开发,注册,商业里程碑付款中获得高达1.35亿美元的收益,以及额外的二位数销售授权费。

• AUM and Newsoara will co-discover up to 5 first-in-class programs that target critical biological pathways
AUM和恒翼生物将共同发现多达5个针对关键生物途径的first-in-class药物

• AUM retains worldwide ex-Greater China rights, and Newsoara retains Greater China rights for all newly discovered candidates
对所有新发现的候选化合物,AUM拥有除大中华区外的全球权益,恒翼生物拥有大中华区权益

• AUM expands its access to the world renowned Suzhou biotech ecosystem, and boosts its strong discovery and significant manufacturing capabilities in Suzhou BioBAY to drive its “Asia to Global” strategy
AUM将入驻苏州生物医药产业园,通过增强其强大的研发及生产能力,以推动其“亚洲走向全球”的战略。

Transaction Overview 交易概览

November 18, 2020, Singapore – AUM Biosciences (AUM), a global, clinical stage healthcare company focused on discovering, acquiring and developing novel oncology therapeutics and Newsoara Biopharma announced today that the companies have entered into a 5-year strategic partnership to co-develop up to 6 oncology drugs in AUM’s pipeline.

2020年11月18日,新加坡–专注于发现,收购和开发新型肿瘤疗法的全球临床阶段医疗保健公司AUM Biosciences(AUM)今天与Newsoara Biopharma(恒翼生物)宣布,两家公司已达成为期5年的战略合作伙伴关系,以共同在AUM的管道中开发多达6种抗肿瘤药物。

The partnership combines AUM’s world-class discovery and clinical development capabilities with Newsoara’s strong discovery, development, and manufacturing capabilities in China.

该合作伙伴关系将AUM的世界级发现和临床开发能力与恒翼生物在中国的强大发现,开发和制造能力相结合。

Under the terms of the Agreement, AUM will receive an undisclosed collaboration fee upon closing. AUM will license exclusive greater China rights of AUM001, AUM302 and AUM003 upon closing of this Agreement, and up to a further 3 candidates for a maximum of 6 oncology drugs.

根据该协议的条款,AUM将在交易完成后收取合作费(金额未披露)。本协议完成后,恒翼生物将获得AUM001,AUM302和AUM003在大中华区的独家许可,以及最多可授予3种候选化合物,最多可使用6种抗肿瘤药。

AUM will receive up to $130 Million in near term development, regulatory, commercial milestones and additional double-digit royalty payments. Newsoara will be responsible for all development and commercialisation and will contribute for potential R&D funding for current and future investigational compounds in greater China.

AUM将在近期开发,注册,商业里程碑以及额外的两位数特许权使用费中获得高达1.3亿美元的收益。 恒翼生物将负责在大中华地区的所有开发和商业化,并将为当前和未来的研究化合物提供潜在的研发资金。

AUM and Newsoara will co-discover and co-fund first-in-class therapeutics for mutually agreed novel targets. AUM retains worldwide rights ex-greater China and Newsoara retains greater China rights for these newly discovered compounds.

AUM和恒翼生物将共同研发选定的first-in-class疗法。对所有新发现的候选化合物,AUM拥有除大中华区外的全球权益,恒翼生物拥有大中华区权益。

Newsoara’s CEO, Benny Li will join AUM’s Board of Directors.

恒翼生物的首席执行官Benny Li将加入AUM的董事会。

Newsoara is an ideal partner for AUM with its focus to provide novel and differentiated therapies for unmet medical needs in China ,” said Vishal Doshi, CEO, AUM Biosciences. “This collaboration is foundational for AUM and will allow us to act as one team to maximize the clinical and commercial potential of AUM’s molecules, greatly amplifying and expediting the opportunities in our pipeline. This partnership accelerates AUM’s path to becoming an independent, fully integrated biopharmaceutical company. It has been a pleasure to have a seasoned, professional and a reliable team like YAFO representing AUM in China. Their China experience and strong networks makes them a strong partner for AUM and its China plans.”

AUM Biosciences首席执行官Vishal Doshi表示:“ Newsoara是AUM的理想合作伙伴,其重点是为中国未满足的医疗需求提供创新且独特的疗法。” “这项合作将使我们能够成为一个团队,最大限度地发挥AUM的产品在临床和商业上的潜力,从而极大地扩大和加速我们的产品开发机会。这种伙伴关系也将帮助AUM更快地成为一家独立的,综合性的生物制药公司。我们很高兴选择雅法资本,这样一支经验丰富、专业且可靠的团队作为AUM在中国的独家财务顾问。他们的中国经验和强大的人脉使其成为AUM和AUM实施其未来中国计划的强大合作伙伴。”

AUM is building a diverse portfolio of small molecule therapeutics that target critical biological pathways. A core component of AUM’s strategy is mandating biomarkers and leveraging AI to systematically discover and develop targeted cancer therapies. Additionally, AUM has a strong focus on the development of intra-portfolio combinations that include small molecules. Through its “Asia to Global” Strategy, including this partnership, AUM will expedite drug development to meet unmet medical needs for patients globally.

AUM正在建立针对关键生物学途径的多样化小分子疗法产品组合。 AUM战略的核心内容是强制使用生物标记物,并利用AI系统地发现和开发针对性的癌症疗法。 另外,AUM非常重视包括小分子在内的投资组合内组合的开发。 通过包括该合作伙伴关系在内的“亚洲到全球”战略,AUM将加快药物开发,以满足全球患者未满足的医疗需求。

“We are very pleased to build on Newsoara’s growing presence in China with this important new strategic collaboration with AUM,” said Benny Li, CEO, Newsoara Biopharma. “Newsoara is committed to developing first-in-class programs for Chinese population and our agreement with AUM further demonstrates that commitment. By gaining access to each other’s diverse pipeline and AUM’s clear strengths and world-class experts in discovery and development, we believe that our partnership with AUM will significantly accelerate our progress in developing next generation therapies for Chinese patients.”

Newsoara Biopharma首席执行官Benny Li表示:“我们很高兴能通过与AUM进行的这一重要的新战略合作,来巩固Newsoara在中国不断增长的业务地位。” “ Newsoara致力于为中国人口开发first-in-class药物,我们与AUM的协议进一步证明了这一承诺。通过共享双方的多样化资产以及AUM在发现和开发方面的明显优势以及世界一流的专家,我们相信,与AUM的合作将大大加快我们为中国患者开发下一代疗法的进程。”

YAFO Capital (Shanghai) Co. Ltd acted as financial advisor on this transaction for AUM Biosciences.

雅法担任AUM Biosciences独家顾问,完成与Newsoara Biopharma合作开发及商业许可交易。

About AUM Biosciences

AUM is a clinical-stage biopharmaceutical company with a focus on discovering, acquiring, and developing novel therapeutics in oncology. AUM utilizes AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets. The management team has an extensive track record of selecting distinctive early stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability and scalability.

总部位于瑞士La-Chaux-de-Fonds的Rhizen制药是一家创新的临床阶段生物制药公司,致力于开发治疗癌症、免疫和代谢紊乱的新型治疗药物。2008年成立以来,已经开发了多种针对多种癌症和免疫相关细胞通路的专利药物候选药。 

About Newsoara 关于恒翼生物

Newsoara is an innovative clinical-stage biopharmaceutical company with a mission to develop and commercialize life changing medicines for cancer, autoimmune, metabolic and other major diseases to patients in China and around the world. Since its founding, Newsoara has developed a fully integrated platform which includes R&D, CMC and clinical development capabilities and built a robust and broad pipeline of 15 drug candidates in major therapeutics areas.

Newsoara是一家创新的临床阶段生物制药公司,致力于为中国和世界各地的患者开发治疗癌症、自身免疫性疾病、代谢等重大疾病的改变生命的药物,并将其商业化。自成立以来,Newsoara已建立了包括研发、CMC和临床开发能力在内的完整集成平台,并在主要治疗领域建立了15种候选药物的强大而广泛的产品线。Newsoara组建了一个在创新药物开发方面具有丰富经验的世界级管理团队,致力于改善和影响全球人类健康。

About YAFO Life Science 雅法全球医疗

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗(YAFO Life Science)是雅法资本旗下的医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作;为中国医疗企业提供产品全球授权、海外市场研究服务,寻找海外投资并购标的,及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验;雅法庞大的海外的区域合伙人团队,均具20+年医药行业及交易经验,覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系:黎琦 | BD Director | 13621979227 | qli@yafocapital.com

Contact 联系我们:

Wendi Xiang, VP, YAFO Capital

T: +86 137 3368 5995

E: wxiang@yafocapital.com